Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Abstract In this phase I dose-escalation trial, we assess the maximum tolerated dose (MTD) of Bermekimab in combination with Nanoliposomal Irinotecan (Nal-Iri) and 5-Fluorouracil/Folinic Acid (5-FU/FA). Secondarily, we investigate effects on weight, lean body mass, quality-of-life, the gut microbiom...

Full description

Bibliographic Details
Main Authors:	Jun Gong, Shant Thomassian, Sungjin Kim, Gillian Gresham, Natalie Moshayedi, Jason Y. Ye, Julianne C. Yang, Jonathan P. Jacobs, Simon Lo, Nick Nissen, Srinivas Gaddam, Mourad Tighiouart, Arsen Osipov, Andrew Hendifar
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-09-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-022-19401-3

Similar Items

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
by: Jun Gong, et al.
Published: (2022-11-01)

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
by: Se Jun Park, et al.
Published: (2021-11-01)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
by: Eric M. Anderson, et al.
Published: (2021-11-01)

A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
by: Jung Won Chun, et al.
Published: (2022-08-01)

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
by: Letizia Procaccio, et al.
Published: (2023-07-01)

Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic Cancer: A Multicenter, Prospective Observational Study
by: Masami Miki, et al.
Published: (2022-08-01)

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
by: Lise Verbruggen, et al.
Published: (2023-08-01)

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
by: Marloes Zoetemelk, et al.
Published: (2020-06-01)

Safety and efficacy of weekly 5-fluorouracil/ folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer
by: Stefan Peinert, et al.
Published: (2010-05-01)

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
by: Takeshi Kawakami, et al.
Published: (2023-01-01)

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
by: Höhler Thomas, et al.
Published: (2004-07-01)

FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial
by: Xiaowei Zhang, et al.
Published: (2022-01-01)

Correlation of <i>UGT1A1</i> Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
by: Kazuaki Harada, et al.
Published: (2023-02-01)

FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study
by: Satoshi Kobayashi, et al.
Published: (2023-02-01)

Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer
by: Ryoji Takada, et al.
Published: (2023-07-01)

Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer
by: FNU Asad ur Rahman, et al.
Published: (2017-07-01)

Durable complete response in a patient with metastatic left‐sided colon cancer treated with 5‐fluorouracil, folinic acid, and irinotecan (FOLFIRI) and panitumumab: A case report
by: Esther Kim, et al.
Published: (2019-07-01)

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
by: Cals Laurent, et al.
Published: (2009-04-01)

5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.
by: Jebb, SA, et al.
Published: (1994)

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
by: Ko AH
Published: (2016-03-01)

Scleroderma after 5-fluorouracil and folinic acid therapy in a patient with colon carcinoma
by: Didem Arslan TAŞ, et al.
Published: (2014-07-01)

IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2008-09-01)

A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis
by: Nicky Solomonidi, et al.
Published: (2023-09-01)

Adjuvant chemoradiotherapy combined with cisplatin, 5-fluorouracil and folinic acid for locally advanced gastric cancer
by: Muharrem Kocar, et al.
Published: (2016-04-01)

Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma
by: David Machover, et al.
Published: (2022-05-01)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
by: Kenneth H. Yu, et al.
Published: (2021-07-01)

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
by: Hélène Bellio, et al.
Published: (2021-10-01)

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
by: Takuo Yamai, et al.
Published: (2022-04-01)

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
by: Kenneth H. Yu, et al.
Published: (2023-04-01)

The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy.
by: Grumett, SA, et al.
Published: (2001)

Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas
by: David Machover, et al.
Published: (2021-06-01)

A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer
by: Tatsuki Ikoma, et al.
Published: (2023-05-01)

Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting
by: Liang, Barry J, et al.
Published: (2020)

Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting
by: Barry J. Liang, et al.
Published: (2020-01-01)

A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases
by: Kobe Van Bael, et al.
Published: (2015-01-01)

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
by: Tej Tummala, et al.
Published: (2023-10-01)

Ostwald-folin pipettes
by: 8096 British Standards Institution

Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.
by: Kerr, D, et al.
Published: (2003)

MTHFR (C677T) polymorphism determination in patients with metastatic colon cancer and its effect on the treatment with 5-fluorouracil and folinic acid
by: Herrera Roberto, et al.
Published: (2007-02-01)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
by: Taieb, J, et al.
Published: (2012)